Developing novel inhaled bioengineered Extracellular Vesicle RNA based advanced therapeutics, delivered by tailored aerosol delivery technology for the treatment of lung cancer

Lung cancer (LC) treatments have advanced in recent years with the advent of genetic profiling and immunotherapy. However, LC is a complex heterogeneous disease and survival rates remain poor.

RNA (mRNA, microRNA, other non-coding RNAs and nucleic acid based modulators of same) and gene therapies (DNA or gene editing) for delivering nucleic acid-based therapeutics have curative potential for a host of indications previously untreatable.

They have yet to enter the mainstream, due to safety concerns and difficulties delivering them efficiently to areas other than the liver, kidney and circulatory system.

Aerosol delivery allows direct targeting of lung tissues but viscous mucus in the lung is a significant barrier to gene transfer to the target cells of the lungs.

Even if the mucus layer can be penetrated, inefficient penetration through the cell membrane further impedes access of these vectors to the underlying target cells, thus preventing successful gene transfer.

Delivery is a major barrier to successful pulmonary gene therapy for competing viral and non-viral gene transfer vectors and the vast promise of gene therapy has many challenges to overcome.

OMNI's novel solution is pioneering the use of genetically modified MSC EVs with a proprietary surface engineering technology to further enhance delivery through the mucus barrier and into the targeted lung cells.

This platform technology also combines efficient aerosol delivery of the EVs via AERO's proprietary state of the art vibrating mesh nebulizer technology. This unique solution solves the problems associated with lung targeted delivery of RNA based advanced therapies.